Home›Research›Compare›Larazotide vs TB-500
Peptide ComparisonLarazotide vs TB-500
Both are Tissue Repair peptides.
Larazotide
AT1001
Half-life: ~30 minutes (local gut action)
11 providers listed
TB-500
thymosin beta 4
Half-life: 5–7 days
402 providers listed
Larazotide carries stronger published evidence (RCT, 3 key studies) than TB-500 (Review, 3); both are research compounds.
Larazotide
Evidence
Half-life
~30 minutes (local gut action)
TB-500
Evidence
Half-life
5–7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Larazotide |
| Further along in FDA review | Larazotide |
| Less frequent dosing (longer half-life) | TB-500 |
| Oral administration option | Larazotide |
| More provider options (11 vs 402) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Larazotide
TB-500
Larazotide
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized control…
Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stre…
A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during glu…
TB-500
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
About Larazotide
Synthetic octapeptide that prevents zonulin-mediated tight junction opening; maintains intestinal epithelial barrier integrity
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Larazotide
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Larazotide
Not enough vendor pricing yet.
TB-500
Where to source these peptides
Larazotide
11 listed
Browse directory →
Providers offeringTB-500
402 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Larazotide vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/larazotide/tb-500